From Table 3, it is evident that the most common clinical investigations involve the combination of recently FDA-approved HIF-2α inhibitors[132] with TKIs, which aligns with the previously described pivotal role of the HIF-2α pathway in renal cancer angiogenesis, particularly in TKI resistance[30,49,107,133]. The gene discussed is EPAS1; the disease is renal carcinoma.